<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02737462</url>
  </required_header>
  <id_info>
    <org_study_id>CG200745-2-02</org_study_id>
    <nct_id>NCT02737462</nct_id>
  </id_info>
  <brief_title>Phase 1/2 Study of CG200745 PPA for Myelodysplastic Syndrome</brief_title>
  <official_title>A Phase I/II Study of CG200745 PPA to Determine the Maximum Tolerated Dose and Evaluate the Safety and Efficacy in Patients With Myelodysplastic Syndrome (MDS) Who Failed to Respond to Prior Hypomethylating Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CrystalGenomics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CrystalGenomics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      &lt;Part I - Phase I trial&gt; The phase I clinical trial is to identify the MTD (Maximum Tolerated&#xD;
      Dose) and DLT (Dose Limiting Toxicity) of CG200745 PPA. Initial dose of CG200745 PPA is 150&#xD;
      mg/m^2, and it will be extended to 225 mg/m^2, 300 mg/m^2 or it will be reduced to 75 mg/m^2&#xD;
      based on the results of the cohort of 3 subjects per dose level.&#xD;
&#xD;
      Based on the 3+3 dose escalation study design, CG200745 PPA is to be administered as in four&#xD;
      different cohorts according to the dose level. Each cohort consists of 3 or 6 subjects.&#xD;
&#xD;
      &lt;Part II - Phase II trial&gt; In the phase II clinical trial, the subjects will be administered&#xD;
      with the dose which is to be identified as a recommended dose based on the results of Phase I&#xD;
      study. The whole one cycle is consisted of 28 days, same as the phase I. The entire treatment&#xD;
      period is 6 cycles and tumor assessment is evaluated every 2 cycles.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      &lt;Part I - Phase I trial&gt; The phase I clinical trial is to identify the MTD and DLT of&#xD;
      CG200745 PPA. Initial dose of CG200745 PPA is 150 mg/m^2, and it will be extended to 225&#xD;
      mg/m^2, 300 mg/m^2 or it will be reduced to 75 mg/m^2 based on the results of the cohort of 3&#xD;
      subjects per dose level.&#xD;
&#xD;
      Based on the 3+3 dose escalation study design, CG200745 PPA is to be administered as in four&#xD;
      different cohorts according to the dose level. Each cohort consists of 3 or 6 subjects.&#xD;
&#xD;
        -  Dose Level -1: CG200745 PPA 75 mg/m^2 x 5 (375 mg/m^2/cycle) / -50%&#xD;
&#xD;
        -  Dose Level 1: CG200745 PPA 150 mg/m^2 x 5 (750 mg/m^2/cycle) / initial base dose&#xD;
&#xD;
        -  Dose Level 2: CG200745 PPA 225 mg/m^2 x 5 (1,125 mg/m^2/cycle) / 50%&#xD;
&#xD;
        -  Dose Level 3: CG200745 PPA 300 mg/m^2 x 5 (1,500 mg/m^2/cycle) / 33%&#xD;
&#xD;
      &lt;Part II - Phase II trial&gt; In the phase II clinical trial, the subjects will be administered&#xD;
      with the dose which is to be identified as a recommended dose based on the results of Phase I&#xD;
      study. The whole one cycle is consisted of 28 days, same as the phase I. The entire treatment&#xD;
      period is 6 cycles and tumor assessment is evaluated every 2 cycles.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>up to 6 cycles (each cycle is 28 days)</time_frame>
    <description>ORR is the proportion of the subjects with Complete Response (CR), Partial Response (PR), marrow CR (mCR), and hematological improvement (HI) in comparison to the total subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve [AUC]</measure>
    <time_frame>Part I, Cycle 1, Day 1, up to 6 days</time_frame>
    <description>Pharmacokinetics (PK) parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration [Cmax]</measure>
    <time_frame>Part I, Cycle 1, Day 1, up to 6 days</time_frame>
    <description>Pharmacokinetics (PK) parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>up to 6 cycles</time_frame>
    <description>Safety parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical laboratory tests</measure>
    <time_frame>up to 6 cycles</time_frame>
    <description>Safety parameter</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>CG200745 PPA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CG200745 PPA intravenously daily for first 5 consecutive days per cycle (4 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CG200745 PPA</intervention_name>
    <description>CG200745 PPA intravenously daily for first 5 consecutive days per cycle (4 weeks)</description>
    <arm_group_label>CG200745 PPA</arm_group_label>
    <other_name>CG200745 PPA (phosphoric acid)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ages: 20 years and above&#xD;
&#xD;
          -  Patient with MDS according to French-American-British (FAB) classification&#xD;
&#xD;
          -  Patients who failed to respond to prior hypomethylating agents (5-azacytidine,&#xD;
             decitabine)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status: 0-2&#xD;
&#xD;
          -  Adequate renal and hepatic function&#xD;
&#xD;
               -  Total serum bilirubin ≤ 3 x Upper Limit Normal (ULN) (except for the case of&#xD;
                  increased unconjugated bilirubin)&#xD;
&#xD;
               -  Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), and Alkaline&#xD;
                  phosphatase (ALP) &lt; 3 x ULN&#xD;
&#xD;
               -  Calculated Glomerular Filtration Rate (GFR) ≥ 50&#xD;
&#xD;
                    -  Modification of Diet in Renal Disease (MDRD)-GFR (mL/min/1.73m2) (for&#xD;
                       female): 186 x (serum creatinine concentration)-1.154 x (age)-0.203 x 0.742&#xD;
                       (for female)&#xD;
&#xD;
          -  Fertile patients, except post-menopausal patients (no menstruation for at least 2&#xD;
             years) or proof of surgical sterility, must use effective contraception up to 3 months&#xD;
             after the completion or withdrawal of the study.&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Patient who understand the overall procedures and requirements of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Peripheral or bone marrow blasts: &gt; 30%&#xD;
&#xD;
          -  Less than 4 weeks since major surgery or radiotherapy&#xD;
&#xD;
          -  Patient with clinically meaningful and relevant, active Central Nerve System (CNS)&#xD;
             disorder&#xD;
&#xD;
          -  Patient with active liver disease&#xD;
&#xD;
          -  Patient with HIV positive&#xD;
&#xD;
          -  Hyper-sensitivity to study drug or similar substances of the drugs&#xD;
&#xD;
          -  Prior Histone Deacetylase (HDAC) inhibitor therapy&#xD;
&#xD;
          -  Less than 4 weeks since hypomethylating agent or cytotoxic drug therapy&#xD;
&#xD;
          -  Less than 4 weeks since immunosuppressive drug therapy&#xD;
&#xD;
          -  Patient who participated in another clinical trial within past 4 weeks&#xD;
&#xD;
          -  Patient who have severe diseases:&#xD;
&#xD;
               -  Severe cardiovascular diseases (severe or unstable angina, congestive heart&#xD;
                  failure, myocardial infarction within past 1 year, uncontrolled hypertension and&#xD;
                  uncontrolled arrhythmia)&#xD;
&#xD;
               -  Neurological or psychiatric disorder&#xD;
&#xD;
               -  Active uncontrolled infection&#xD;
&#xD;
               -  Any other diseases that may interfere with the interpretation of study result&#xD;
                  (according to the judgment of investigator)&#xD;
&#xD;
          -  Pregnancy or lactating&#xD;
&#xD;
          -  Patient who is not considered to be appropriate for the study according to the&#xD;
             judgment of investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Je-Hwan Lee, M.D., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jun Ho Jang, M,D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sung-soo Yoon, M,D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sangsook Cho, Ph.D.</last_name>
    <phone>+1 925 876 1975</phone>
    <email>scho@cgxinc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chohee Park</last_name>
    <phone>+82 31 628 2872</phone>
    <email>chpark@cgxinc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asan Medical Center, Samsung Medical Center, Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sujeong Kim, R.N.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>March 22, 2016</study_first_submitted>
  <study_first_submitted_qc>April 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2016</study_first_posted>
  <last_update_submitted>June 13, 2019</last_update_submitted>
  <last_update_submitted_qc>June 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

